# A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

> **NCT01941095** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 100 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Azathioprine
- **DRUG:** Chloroquine
- **DRUG:** Hydroxychloroquine
- **DRUG:** Leflunomide
- **DRUG:** Methotrexate
- **DRUG:** Sulfasalazine
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01941095
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-20
- **Primary completion:** 2016-07-10
- **Final completion:** 2016-07-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941095, "A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT01941095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*